Dataset from A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)

The clinical study will evaluate safety and the immune response of a prime- boost regimen
with a live attenuated influenza vaccine (LAIV) prime and an inactivated split influenza
vaccine (IIV) boost with or without adjuvant.

本临床研究将评估初免-加强免疫方案（prime-boost regimen）的安全性与免疫应答，该方案以减毒活流感疫苗（live attenuated influenza vaccine, LAIV）进行初免，以裂解灭活流感疫苗（inactivated split influenza vaccine, IIV）实施加强免疫，且加强免疫环节可选择添加或不添加佐剂（adjuvant）。